Cite
MLA Citation
Sabina Kersting et al.. “Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial.” Lancet, vol. 9, no. 3, 2022, pp. e190–e199. http://access.bl.uk/ark:/81055/vdc_100152304896.0x000004